Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of AphroFemine vs Addyi (Flibanserin) in Healthy Females
NCT04494191Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of flibanserin in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2018; status: completed.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT04494191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494191.